



# Molecular Therapy

Commentary



## Commentary

- Haemophilia. 27, 947–956. <https://doi.org/10.1111/hae.14391>.
11. Nathwani, A.C., Tuddenham, E.G.D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D.C., Chowdary, P., Riddell, A., Pie, A.J., Harrington, C., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. *N. Engl. J. Med.* 365, 2357–2365. <https://doi.org/10.1056/NEJMoa1108046>.
  12. Huang, D.Q., El-Serag, H.B., and Loomba, R. (2021). Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. *Nat. Rev. Gastroenterol. Hepatol.* 18, 223–238. <https://doi.org/10.1038/s41575-020-00381-6>.
  13. Konkle, B.A., Pierce, G.F., Coffin, D., Naccache, M., Clark, C., George, L.A., Iorio, A., O'Mahony, B., Pipe, S., Skinner, M.W., et al. (2020). Core data set on safety, efficacy and durability of hemophilia gene therapy for a global registry: communication from the SSC of the ISTH. *J Thromb Haemost.* 18, 3074–3077. <https://doi.org/10.1111/jth.15023>.
  14. Miao, H.Z., Sirachainan, N., Palmer, L., Kucab, P., Cunningham, M.A., Kaufman, R.J., and Pipe, S.W. (2004). Bioengineering of coagulation factor VIII for improved secretion. *Blood* 103, 3412–3419. <https://doi.org/10.1182/blood-2003-10-3591>.
  15. Cao, W., Dong, B., Horling, F., Firman, J.A., Lengler, J., Klugmann, M., de la Rosa, M., Wu, W., Wang, Q., Wei, H., et al. (2020). Minimal essential human factor VIII alterations enhance secretion and gene therapy efficiency. *Mol. Ther. Methods Clin. Dev.* 19, 486–495. <https://doi.org/10.1016/j.omtm.2020.10.013>.